Early	early	O	O	O	O
adjuvant	adjuvant	O	O	O	O
adriamycin	adriamycin	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
superficial	superficial	O	O	O	O
bladder	bladder	O	O	O	O
carcinoma	carcinoma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
multicenter	multicenter	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
performed	performed	O	O	O	O
in	in	O	O	O	O
110	110	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
superficial	superficial	O	O	O	O
transitional	transitional	O	O	O	O
cell	cell	O	O	O	O
carcinoma	carcinoma	O	DISEASE	OTHERS	I
of	of	O	O	O	O
the	the	O	O	O	O
bladder	bladder	O	O	O	O
.	.	O	O	O	O

Adriamycin	adriamycin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
50	50	O	O	O	O
mg/50	mg/50	O	O	O	O
ml	ml	O	O	O	O
)	)	O	O	O	O
was	was	O	O	O	O
administered	administered	O	O	O	O
intravesically	intravesically	O	O	O	O
within	within	O	O	O	O
24	24	O	O	O	O
h	h	CHEMICALS	O	OTHERS	I
after	after	O	O	O	O
transurethral	transurethral	O	O	O	O
resection	resection	O	O	O	O
of	of	O	O	O	O
TA-T1	ta-t1	O	O	O	O
(	(	O	O	O	O
O-A	o-a	O	O	O	O
)	)	O	O	O	O
bladder	bladder	O	O	OTHERS	I
tumors	tumors	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Instillation	instillation	O	O	O	O
was	was	O	O	O	O
repeated	repeated	O	O	O	O
twice	twice	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
week	week	O	O	O	O
,	,	O	O	O	O
then	then	O	O	O	O
weekly	weekly	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
month	month	O	O	O	O
and	and	O	O	O	O
afterwards	afterwards	O	O	O	O
monthly	monthly	O	O	O	O
for	for	O	O	O	O
1	1	O	O	O	O
year	year	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
tolerance	tolerance	O	O	O	O
was	was	O	O	O	O
evaluated	evaluated	O	O	O	O
in	in	O	O	O	O
these	these	O	O	O	O
110	110	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
29	29	O	O	O	O
patients	patients	O	O	O	O
presented	presented	O	O	O	O
with	with	O	O	O	O
local	local	O	O	O	O
side-effects	side-effects	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
24	24	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
patients	patients	O	O	O	O
chemical	chemical	O	O	O	O
cystitis	cystitis	O	DISEASE	OTHERS	I
was	was	O	O	O	O
severe	severe	O	O	O	O
enough	enough	O	O	O	O
for	for	O	O	O	O
them	them	O	O	O	O
to	to	O	O	O	O
drop	drop	O	O	O	O
out	out	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
systemic	systemic	O	O	O	O
side-effects	side-effects	O	O	O	O
were	were	O	O	O	O
observed	observed	O	O	O	O
.	.	O	O	O	O

Recurrence	recurrence	O	O	O	O
was	was	O	O	O	O
studied	studied	O	O	O	O
in	in	O	O	O	O
82	82	O	O	O	O
evaluable	evaluable	O	O	O	O
patients	patients	O	O	O	O
after	after	O	O	O	O
1	1	O	O	O	O
year	year	O	O	O	O
of	of	O	O	O	O
follow-up	follow-up	O	O	O	O
and	and	O	O	O	O
in	in	O	O	O	O
72	72	O	O	O	O
patients	patients	O	O	O	O
followed	followed	O	O	O	O
for	for	O	O	O	O
2	2	O	O	O	O
-	-	O	O	O	O
3	3	O	O	O	O
years	years	O	O	O	O
(	(	O	O	O	O
mean	mean	O	O	O	O
32	32	O	O	O	O
months	months	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Of	of	O	O	O	O
the	the	O	O	O	O
82	82	O	O	O	O
patients	patients	O	O	O	O
studied	studied	O	O	O	O
after	after	O	O	O	O
1	1	O	O	O	O
year	year	O	O	O	O
,	,	O	O	O	O
23	23	O	O	O	O
had	had	O	O	O	O
primary	primary	O	O	O	O
and	and	O	O	O	O
59	59	O	O	O	O
recurrent	recurrent	O	O	O	O
disease	disease	O	O	O	O
.	.	O	O	O	O

Of	of	O	O	O	O
the	the	O	O	O	O
82	82	O	O	O	O
evaluable	evaluable	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
50	50	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
show	show	O	O	O	O
any	any	O	O	O	O
recurrence	recurrence	O	O	O	O
after	after	O	O	O	O
1	1	O	O	O	O
year	year	O	O	O	O
(	(	O	O	O	O
61	61	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
while	while	O	O	O	O
32	32	O	O	O	O
presented	presented	O	O	O	O
with	with	O	O	O	O
one	one	O	O	O	O
or	or	O	O	O	O
more	more	O	O	O	O
recurrences	recurrences	O	O	O	O
(	(	O	O	O	O
39	39	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Of	of	O	O	O	O
these	these	O	O	O	O
recurrences	recurrences	O	O	O	O
,	,	O	O	O	O
27	27	O	O	O	O
were	were	O	O	O	O
T1	t1	O	O	O	O
tumors	tumors	O	DISEASE	OTHERS	I
while	while	O	O	O	O
five	five	O	O	O	O
progressed	progressed	O	O	O	O
to	to	O	O	O	O
more	more	O	O	O	O
highly	highly	O	O	O	O
invasive	invasive	O	O	O	O
lesions	lesions	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
patients	patients	O	O	O	O
that	that	O	O	O	O
were	were	O	O	O	O
free	free	O	O	O	O
of	of	O	O	O	O
recurrence	recurrence	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
year	year	O	O	O	O
,	,	O	O	O	O
80	80	O	O	O	O
%	%	O	O	O	O
remained	remained	O	O	O	O
tumor-free	tumor-free	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
2-	2-	O	O	O	O
to	to	O	O	O	O
3-year	3-year	O	O	O	O
follow-up	follow-up	O	O	O	O
period	period	O	O	O	O
.	.	O	O	O	O

Of	of	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
developing	developing	O	O	O	O
one	one	O	O	O	O
or	or	O	O	O	O
more	more	O	O	O	O
recurrences	recurrences	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
year	year	O	O	O	O
,	,	O	O	O	O
only	only	O	O	O	O
50	50	O	O	O	O
%	%	O	O	O	O
presented	presented	O	O	O	O
with	with	O	O	O	O
further	further	O	O	O	O
recurrence	recurrence	O	O	O	O
once	once	O	O	O	O
the	the	O	O	O	O
instillations	instillations	O	O	O	O
were	were	O	O	O	O
stopped	stopped	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
beneficial	beneficial	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
Adriamycin	adriamycin	CHEMICALS	O	OTHERS	I
appears	appears	O	O	O	O
obvious	obvious	O	O	O	O
and	and	O	O	O	O
might	might	O	O	O	O
be	be	O	O	O	O
related	related	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
itself	itself	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
early	early	O	O	O	O
and	and	O	O	O	O
repeated	repeated	O	O	O	O
instillations	instillations	O	O	O	O
after	after	O	O	O	O
TUR	tur	O	O	O	O
,	,	O	O	O	O
or	or	O	O	O	O
both	both	O	O	O	O
.	.	O	O	O	O

